WorldCat Identities

Meijer, C.J.L.M. (Christophorus Joannes Lambertus Maria) 1945-

Works: 8 works in 10 publications in 2 languages and 20 library holdings
Genres: Scientific atlases  Academic theses 
Roles: Author, dgs
Classifications: RC280.L9, 616.99442
Publication Timeline
Most widely held works by C.J.L.M Meijer
De specifiek cellulaire response : een kwalitatief en kwantitatief onderzoek naar de morfologische en enzymatische veranderingen in lymfeklieren na toediening van de kontaktsensibilisator DNCB by Christophorus Joannes Lambertus Maria Meijer( Book )

2 editions published in 1971 in Dutch and held by 7 WorldCat member libraries worldwide

Malignant lymphomas : cytology, histopathology, and immunochemistry : an atlas and textbook( Book )

1 edition published in 1996 in English and held by 4 WorldCat member libraries worldwide

"Insight into lymphocyte biology and traffic, the availability of monoclonal antibodies against lymphocyte differentiation antigens and last, but not least, the development of molecular biological techniques have considerably extended our knowledge about lymphomas. In recent years it has been recognized that extranodal lymphomas behave differently from nodal lymphomas." "This book, based on the experience of the Amsterdam lymphoma panel, provides the theoretical background for understanding and classifying lymphomas." "The updated Kiel classification for Non-Hodgkin's lymphomas and the revised European-American classification of lymphomas (REAL) are used throughout the book, with the Working Formulation for comparison." "Each chapter presents data in succession on clinical findings, cytology, histology, immunocytochemistry, and, where pertinent, electron microscopy and molecular biology." "The latest version (1 February 1995) of the full CD list of monoclonal antibodies is provided."--BOOK JACKET
Modeling the effects of cervical cancer prevention in the Netherlands by Annelie Vink( Book )

1 edition published in 2015 in English and held by 3 WorldCat member libraries worldwide

HPV and cervical cancer on Curaçao : towards implementation of an integrated prevention programme by Desiree Jasmin Hooi( Book )

2 editions published in 2018 in English and held by 2 WorldCat member libraries worldwide

Clinical validation of the Abbott RealTime High Risk (HR) HPV assay according to the guidelines for HPV DNA test requirements for cervical screening( )

1 edition published in 2013 in English and held by 1 WorldCat member library worldwide

This study showed that the Abbott RealTime High-Risk (HR) HPV assay fulfilled cross-sectional clinical equivalence and reproducibility criteria of international consensus guidelines [1], which indicates that this assay can be considered clinically validated for cervical cancer screening purposes
Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?( )

1 edition published in 2015 in English and held by 1 WorldCat member library worldwide

Several countries are in the process of switching to high-risk human papillomavirus (hrHPV) test info cervicar cancer screening. Given the multitude of available tests, validated assays which assure high-quality screening need to be identified. A systematic review was conducted to answer the question which hrHPV tests ful fil the criteria defined by an international expert team in 2009, based on reproducibility and relative sensitivity and specificity compared to Hybrid Capture-2 or GP5+/6+ PCR % enzyme immunoassay. These latter two hrHPV DNA assays were validated in large randomized trials and cohorts with a follow-up duration of 8 years or more. Eligible studies citing the 2009 guideline were retrieved from Scopus ( ) and from a meta-analysis assessing the relative accuracy of new hrHPV assays versus the standard comparator tests to detect high-grade cervical intraepithelial neoplasia or cancer in primary screening. The cobas 4800 HPV test and Abbott RealTime High Risk HPV test were consistently validated in two and three studies, respectively, whereas the PapilloCheck HPV-screening test, BD Onclarity HPV assay and the HPV-Risk assay were validated each in one study. Other tests which partially ful fil the 2009 guidelines are the following: Cervista HPV HR Test, GP5+/6+ PCR-LMNX, an in-house E6/E7 RT quantitative PCR and MALDI-TOF (matrix-assisted laser desorption- ionization time-of- flight). The APTIMA HPV assay targeting E6/E7 mRNA of hrHPV was also fully validated. However, the cross-sectional equivalency criteria of the 2009 guidelines were set up for HPV DNA assays. Demonstration of a low risk of CIN3+ after a negative APTIMA test over a longer period is awaited to inform us about its utility in cervical cancer screening at 5-year or longer intervals
Surveillance of young HPV-positive women below age of 30 by FAM19A4/miR124methylation a multi-center European cohort study( )

1 edition published in 2019 in English and held by 1 WorldCat member library worldwide

Pathologie by P.J Hoedemaeker( Book )

1 edition published in 1995 in Dutch and held by 1 WorldCat member library worldwide

Studieboek op universitair niveau
Audience Level
Audience Level
  Kids General Special  
Audience level: 0.82 (from 0.71 for Malignant ... to 0.96 for Clinical v ...)

English (7)

Dutch (3)